This is all stuff I care about, but none of it was explicitly about me until two weeks ago, when I found out an AI company was selling a product with my name on it. The San Franci ...

I tested a near-infrared light device that attaches to my computer, mimics the sun, and allegedly improves mood and focus. Did it work?

For 20 years, this computational linguistics competition has inspired new generations of innovators in AI and language ...

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization. CSL and Eli Lilly have struck a strategic ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

CSL has dumped chief executive Paul McKenzie after a brutal year for the global biotechnology giant, installing a former senior manager as interim boss following pressure from shareholders for a ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) will be reporting earnings this Tuesday after market close. Here’s what investors should know. Carlisle beat analysts’ revenue ...

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here's why 2026 could look better. CSL experienced a challenging 2025 with shares underperforming the ASX 200 due to ...